Literature DB >> 11566602

'Troy-bodies': antibodies as vector proteins for T cell epitopes.

E Lunde1, I B Rasmussen, J K Eidem, T F Gregers, K H Western, B Bogen, I Sandlie.   

Abstract

A major objective in vaccine development is the design of reagents that give a strong, specific T cell response. Targeting of antigens to antigen presenting cells (APC) results in enhanced antigen presentation and T cell activation. In this paper, we describe a novel targeting reagent denoted 'Troy-bodies', namely recombinant antibodies with APC-specificity and with T cell epitopes integrated in their C regions. We have made such antibodies with V regions specific for either IgD or MHC class II, and five different T cell epitopes have been tested. All epitopes could be introduced into loops of C domains without disrupting immunoglobulin (Ig) folding. Four have been tested in T cell activation studies, and all could be released and presented by APC. Furthermore, whether IgD- or MHC-specific, the molecules tested enhanced T cell stimulation compared to non-specific control antibodies in vitro as well as in vivo. Using this technology, specific reagents can be designed that target selected antigenic peptides to an APC of choice. Troy-bodies may therefore be useful for manipulation of immune responses, and in particular for vaccination purposes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566602     DOI: 10.1016/s1389-0344(01)00091-0

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  2 in total

1.  Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.

Authors:  J Benjamin St Clair; Thiago Detanico; Katja Aviszus; Greg A Kirchenbaum; Merry Christie; John F Carpenter; Lawrence J Wysocki
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

2.  An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.

Authors:  Julie D McIntosh; Kristy Manning; Shilpa Chokshi; Nikolai V Naoumov; John D Fraser; P Rod Dunbar; John A Taylor
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.